Focus Partners Advisor Solutions’s Context Therapeutics CNTX Stock Holding History

Focus Partners Advisor Solutions’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.21K	Buy	+14,007	New	+$6.91K	﹤0.01%	1384

Other funds holding CNTX

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Focus Partners Advisor Solutions's CNTX Position: Q3 2026 in Review

Focus Partners Advisor Solutions opened a new position in Context Therapeutics (CNTX) in Q3 2026: 14,007 shares worth $4.21K. The stake represents ﹤0.01% of the portfolio and ranks #1384 among its holdings.

59 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

Focus Partners Advisor Solutions held 14,007 shares of Context Therapeutics worth $4.21K as of Q3 2026.
Context Therapeutics was a new Focus Partners Advisor Solutions position in Q3 2026.
Context Therapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q3 2026, its #1384 holding.
59 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q3 2026, filed 10 Nov 2026.